Glenmark Life Sciences Limited AI Stock Analysis
Want to see IN:ALIVUS full AI Analyst Report?
Glenmark Life Sciences Limited (ALIVUS) AI Stock Analysis
Glenmark Life Sciences Limited
(NSE:ALIVUS)
Strong financial performance with low leverage and steady profitability is the primary driver, reinforced by bullish technical indicators from moving averages and MACD.
Glenmark Life Sciences Limited (ALIVUS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 178.44B
- Dividend Yield
- 0.35%
- Average Volume (3M)
- 26.10K
- Price to Earnings (P/E)
- 26.6
- Beta (1Y)
- 0.94
- Revenue Growth
- 8.19%
- EPS Growth
- 26.12%
- Country
- India
- Employees
- 2,272
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Glenmark Life Sciences Limited Business Overview & Revenue Model
Company Description
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, prod...
How the Company Makes Money
Glenmark Life Sciences primarily makes money by selling APIs and intermediates to pharmaceutical companies that use these materials to manufacture finished-dose medicines. Revenue is generated through (1) commercial supply of APIs for generic and bra...
Glenmark Life Sciences Limited Financial Statement Overview
Summary
Robust revenue and net income growth, significantly strengthened balance sheet with near-zero debt-to-equity, and consistent operating cash flow generation.
Income Statement
85Very PositiveBalance Sheet
90Very PositiveCash Flow
80Positive| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.91B | 25.52B | 22.83B | 21.61B | 18.85B | 15.37B |
| Gross Profit | 5.31B | 11.37B | 12.43B | 11.47B | 9.80B | 8.47B |
| EBITDA | 3.68B | 8.32B | 6.86B | 6.71B | 5.92B | 4.84B |
| Net Income | 2.53B | 5.64B | 4.71B | 4.67B | 3.52B | 3.13B |
Balance Sheet | ||||||
| Total Assets | 36.38B | 39.83B | 28.50B | 27.02B | 19.97B | 17.26B |
| Cash, Cash Equivalents and Short-Term Investments | 6.53B | 7.83B | 3.01B | 3.80B | 1.40B | 307.68M |
| Total Debt | 1.13B | 567.71M | 171.48M | 193.57M | 9.33B | 210.00K |
| Total Liabilities | 6.23B | 6.51B | 5.18B | 5.64B | 12.44B | 13.24B |
| Stockholders Equity | 30.15B | 33.32B | 23.32B | 21.38B | 7.53B | 4.02B |
Cash Flow | ||||||
| Free Cash Flow | 913.92M | 2.59B | 2.85B | 1.43B | 3.20B | 1.44B |
| Operating Cash Flow | 1.72B | 5.66B | 4.14B | 3.13B | 3.88B | 1.95B |
| Investing Cash Flow | -5.43B | -5.71B | -1.16B | -1.54B | -687.34M | -505.18M |
| Financing Cash Flow | -44.64M | -641.34M | -2.79B | -3.88B | -2.14B | -1.37B |
Glenmark Life Sciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALIVUS, the sentiment is Positive. The current price of 1448.50 is above the 20-day moving average (MA) of 1393.70, above the 50-day MA of 1381.37, and above the 200-day MA of 1149.31, indicating a bullish trend. The MACD of 32.28 indicates Negative momentum. The RSI at 57.55 is Neutral, neither overbought nor oversold. The STOCH value of 34.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALIVUS.
Glenmark Life Sciences Limited Peers Comparison
Overall Rating
IN:ALIVUS80Outperform
IN:DIVISLAB74.3Outperform
IN:GRANULES72Outperform
IN:LAURUSLABS67Neutral
IN:NEULANDLAB60Neutral
IN:SOLARA50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | INR 178.12B | 26.56 | ― | 0.35% | 8.19% | 26.12% | |
| 74Outperform | INR 2.95T | 87.44 | ― | 0.27% | 21.56% | 35.33% | |
| 72Outperform | INR 198.15B | 27.64 | ― | 0.22% | 21.75% | 36.70% | |
| 67Neutral | INR 1.20T | 89.48 | ― | 0.10% | 23.03% | 95.69% | |
| 60Neutral | INR 277.40B | 61.35 | ― | 0.16% | 50.46% | 88.44% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | INR 30.50B | 82.34 | ― | ― | 27.30% | 456.80% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ALIVUS | Glenmark Life Sciences Limited | 1448.50 | 530.28 | 57.75% | |
| IN:DIVISLAB | Divi's Laboratories Limited | 11111.00 | 4662.35 | 72.30% | |
| IN:GRANULES | Granules India Limited | 799.65 | 239.02 | 42.63% | |
| IN:LAURUSLABS | Laurus Labs Ltd. | 2217.05 | 1212.48 | 120.70% | |
| IN:NEULANDLAB | Neuland Laboratories Ltd. | 21621.35 | 4402.93 | 25.57% | |
| IN:SOLARA | Solara Active Pharma Sciences Ltd. | 634.45 | 61.65 | 10.76% |
Glenmark Life Sciences Limited Corporate Events
Alivus Executes Shareholders’ Agreement With IQGEN-X Pharma
Alivus Life Sciences executed a shareholders’ agreement with IQGEN-X Pharma and its continuing existing shareholders, Dr. Mandar Kodgule and Dr. Yogita Kodgule. The agreement records mutual understanding on shareholding-related rights and obligations...
Alivus Life Sciences posts double-digit growth and record margins in Q2FY27
Alivus Life Sciences reported strong results for the quarter ended September 30, 2026, with revenue from operations rising 16.0% year-on-year to Rs. 6,820 million, driven by broad-based momentum in its non-GPL API business and a meaningful pickup in...
Alivus Life Sciences Files Q2 FY26-27 Investor Presentation with Stock Exchanges
Alivus Life Sciences Limited has released its investor presentation for the second quarter of fiscal year 2026-27, complying with disclosure requirements under Indian securities regulations. The filing with BSE and NSE signals routine quarterly commu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
